Thermo Fisher Scientific Stock

Equities

TMO

US8835561023

Advanced Medical Equipment & Technology

Market Closed - Nyse 04:00:01 2024-07-05 pm EDT 5-day change 1st Jan Change
540.1 USD +0.84% Intraday chart for Thermo Fisher Scientific -2.33% +1.75%
Sales 2024 * 43.01B Sales 2025 * 46.05B Capitalization 206B
Net income 2024 * 6.18B Net income 2025 * 6.96B EV / Sales 2024 * 5.33 x
Net Debt 2024 * 23.19B Net Debt 2025 * 19.14B EV / Sales 2025 * 4.89 x
P/E ratio 2024 *
33.7 x
P/E ratio 2025 *
29 x
Employees 122,000
Yield 2024 *
0.28%
Yield 2025 *
0.3%
Free-Float 86.04%
More Fundamentals * Assessed data
Dynamic Chart
Evercore ISI Cuts Price Target on Thermo Fisher Scientific to $600 From $615, Maintains Outperform Rating MT
Verici Dx hails milestone payment in deal with Thermo Fisher AN
Thermo Fisher Scientific Inc.(NYSE:TMO) dropped from Russell Top 200 Growth Index CI
Thermo Fisher Scientific Inc.(NYSE:TMO) dropped from Russell 3000 Growth Index CI
Thermo Fisher Scientific Inc.(NYSE:TMO) dropped from Russell 3000E Growth Index CI
Thermo Fisher Scientific Inc.(NYSE:TMO) dropped from Russell 1000 Growth Index CI
Thermo Fisher Scientific Inc.(NYSE:TMO) dropped from Russell 1000 Growth-Defensive Index CI
Thermo Fisher Scientific Inc. Expands Clinical Research Laboratory in Kentucky CI
Barclays Adjusts Price Target on Thermo Fisher Scientific to $600 From $615 MT
Labguru Announces New Distribution Partnership with Thermo Fisher Scientific of its Electronic Lab Notebook Module to Help Streamline Life Sciences Research CI
Thermo Fisher Scientific Introduces the Only Fully Automated Plasmid Purification System to Help Accelerate Discovery and Development of Therapies CI
RBC Trims Price Target on Thermo Fisher Scientific to $660 From $662, Keeps Outperform Rating MT
Thermo Fisher Scientific Inc. Expands Clinical Research Laboratory in Wisconsin CI
Thermo Fisher Scientific Inc., National University Hospital, Singapore and Mirxes Collaborates to Enhance Access to Advanced Genomic Testing for Early Cancer Detection in Singapore CI
Verici Dx plc Announces Successful Transfer of Urine Samples to Thermo Fisher Scientific CI
More news
1 day+0.84%
1 week-2.33%
Current month-2.33%
1 month-7.05%
3 months-6.79%
6 months+1.67%
Current year+1.75%
More quotes
1 week
532.44
Extreme 532.435
541.59
1 month
532.44
Extreme 532.435
582.28
Current year
527.32
Extreme 527.32
603.82
1 year
415.60
Extreme 415.6
603.82
3 years
415.60
Extreme 415.6
672.34
5 years
250.21
Extreme 250.21
672.34
10 years
107.33
Extreme 107.33
672.34
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 01-10-31
Director of Finance/CFO 57 01-05-31
Chief Tech/Sci/R&D Officer - 18-12-31
Members of the board TitleAgeSince
Chief Executive Officer 56 01-10-31
Director/Board Member 67 12-03-29
Director/Board Member 62 22-02-28
More insiders
Date Price Change Volume
24-07-05 540.1 +0.84% 1,233,257
24-07-03 535.6 +0.31% 908,266
24-07-02 533.9 -1.44% 1,316,367
24-07-01 541.7 -2.04% 1,459,439

Delayed Quote Nyse, July 05, 2024 at 04:00 pm EDT

More quotes
Thermo Fisher Scientific Inc. specializes in the design, manufacturing and marketing of laboratory and scientific equipments. Net sales (including intragroup) break down by family of products as follows: - laboratory equipments (70%). Moreover, the group proposes chemical products (reagents, solvent, salts, etc.), consumable products (tubes, funnels, vials, etc.), as well as conditioning, warehousing, storage, etc.; - diagnostics equipment and products (15.3%); - scientific analysis equipments (14.7%): analyzer (of water, gas, grounds, etc.), mass spectrometers, molecular spectroscopes, microscopes, manometers, samplers, microbiology equipments, reactive agents, etc. Net sales break down by source of income into products sales (78.5%) and services (21.5%). Net sales break down geographically as follows: North America (53%), Europe (25.7%), Asia-Pacific (18.1%) and others (3.2%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
540.1 USD
Average target price
628.2 USD
Spread / Average Target
+16.31%
Consensus